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Abstract 
Objective: To describe incidence patterns and trends in children (0-14 years) and adolescents 
(15-19 age-range) with solid tumours, except those of central nervous system (CNS), in Spain. 
Methods: Cases were drawn from eleven Spanish population-based cancer registries. Incidence 
was estimated for the period 1983-2007 and trends were evaluated using Joinpoint regression 
analysis.  
Results: The studied tumour groups accounted for 36% of total childhood cancers and 47.6% of 
those diagnosed in adolescence with annual rates per million of 53.5 and 89.3 respectively. In 
children 0 to 14 years of age, Neuroblastoma (NB) was the commonest (7.8%) followed by 
Soft-tissue sarcomas (STS) (6.3%), bone tumours (BT) (6.2%) and renal tumours (RT) (4.5%). NB 
was the most frequently diagnosed tumour before the 5th birthday, while STS and BT were the 
commonest at 5-9 years of age, and BT and Carcinoma and other epithelial tumours (COET) at 
10-14. COET presented the highest incidence in adolescents, followed by germ-cell tumours 
(GCT), BT and STS. These four diagnostic groups accounted for 94% of total non-CNS solid 
tumours, in adolescents. Overall incidence rates increased significantly in children up to 1996 with 
an annual percentage change (APC) of 2.6% (95%CI: 1.7; 3.6). NB and COET showed significant 
time trend (APCs: 1.4% and 3.8% respectively) while other tumour groups such as RT, STS, BT or 
GCT had no significant changes over time. A significant increase was present in NB under the age 
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of 5 and in BT and STS in children aged 10-14 years. In adolescents there were significant increases 
for all tumours combined (APC=2.7; 95%CI: 1.8-3.6) and for STS, GCT and COET (APCs: 3.2%, 
4.4% and 3.5% respectively), while other tumour groups such as hepatic tumours, BT or thyroid 
carcinomas showed a decreasing trend or no increase. 
Conclusions: Overall, the incidence of the studied cancers in children increased along the period 
1983-1996 with no posterior significant rise, while the incidence in adolescents increased       
significantly over the whole period 1983-2007. Several specific tumour groups showed significant 
rises or decrements in childhood or adolescence, although the small number of cases precludes 
showing significant trends or inflexion points. 
Key words: cancer, solid tumour, childhood, adolescents, population-based study, incidence, Spain. 
Introduction 
Childhood cancers represent around 0.53% of all 
cancers diagnosed in Spain in 2003-2007 (1) and yet it 
was the most common cause of disease-related death 
for children between 1–14 years of age in 2012 in 
Spain (2). A 0.3% of cancers are diagnosed in the 
adolescence (15-19 years) and the incidence is higher 
than that of childhood cancer (3). 
The most common cancers in childhood are 
leukemia, tumors of the central nervous system (CNS) 
and lymphomas, but there are other solid tumors that 
represent one third of the cancers detected during 
childhood (4) and have not been previously described 
in detailed in Spain. Embryonal cancers that develop 
in childhood are very rare in adolescence and some 
solid tumours, typical in adults (e.g. thyroid cancer 
and melanoma) and rare in childhood, are more 
common in adolescents (3). 
Solid tumour (except CNS) incidence rates in 
children have been increasing in the last decades in 
Spain (4). Similar pattern has been observed in Europe 
(5) except for retinoblastoma, hepatic and bone 
tumours and other and unspecified malignant 
neoplasms. The most recent data available in the 
United States of America (USA) for children and 
adolescents (6) shows an increasing trend in incidence 
for testicular Germ-cell tumours (GCT) and a plateau 
for bone tumours (BT), neuroblastoma (NB), Wilms 
tumour (WT), rhabdomyosarcoma (RMS), 
retinoblastoma and ovarian germ-cell tumours (GCT). 
Even when there is less information on cancer 
incidence in adolescents, there has been an increase in 
Europe over the last two decades of the twenty 
century, especially due to melanoma, thyroid cancer 
and GCT (3) and also in the USA (7) where the largest 
contributor to this increase has been GCT. 
The aim of this study is to describe the latest 
trends in incidence with more detailed analysis on 
non-CNS solid tumours until 2007, following the 
publication on childhood cancer in Spain (4), and to 
describe the characteristics of these tumours in 
adolescents. 
Materials and Methods  
Eleven population-based cancer registries (Table 
1a) participated in this study with children data and 
ten for adolescents. According to the 2001 census, the 
incidence data reported represents 31% of the Spanish 
population aged 0-14 years and 21% of the 15-19 years 
old population. The study period was 1983 to 2007, 
with a slightly different period for each area involved 
(Table 1a). All registries make periodic quality 
controls using international software (8). Data quality 
indicators presented for diagnostic validity are 
microscopic verification (MV), death certificate only 
(DCO) and unspecified histology (NOS). These 
indicators were calculated separately for two periods 
(1983-1992 and 1993-2007), cut point based on the 
inflection point observed in a previous analysis (4). 
The participating registries share uniform and 
standard data collection guidelines that have been 
described elsewhere (9). A case was defined as any 
child aged 0-19 years with a diagnosis of solid 
malignant tumour other than those of CNS, residing 
in the registration areas of the registries included in 
each analysis and incident in the corresponding 
period. Children will be considered all children less 
than 15 years of age and adolescents those aged 15 to 
19 years. Spanish Registry of Childhood Tumours 
(RETI-SEHOP), with national coverage, was used to 
detect cases of cancer residing in the registration areas 
of the regional registries but cared for in other 
geographical areas. The International Classification of 
Diseases for Oncology (ICD-O) second (10) and third 
(11) editions were used for coding; all cases were 
converted into the third edition of the ICD-O and the 
International Classification of Childhood Cancer third 
edition (ICCC-3) (12) was used for defining diagnostic 
groups.  
We included groups IV to XII from the ICCC-3 
for the whole period. Incidence rates were estimated 
for each diagnostic group, sex and age group (0, 1-4, 
5-9, 10-14 and 15-19 years). Rates of children under 15 
years were age standardized to the European (ASRe) 
and world (ASRw) standard populations using the 
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direct method and expressed per million children and 
year. The population at risk was obtained from the 
Spanish Statistical Office and the statistical offices of 
the respective autonomous communities for Albacete, 
Girona, Mallorca, Granada, Tarragona and Zaragoza.  
Five-year periods (1983-1987, 1988-1992, 
1993-1997, 1998-2002 and 2003-2007) ASRe were 
estimated for trend analysis. A Joinpoint regression 
model was used to analyze the time-related trends for 
these tumours, applied to individual years of data. 
This made possible to estimate annual percentage 
change (APC) and to identify trend inflexion points 
when they could be detected (13). A maximum of one 
inflection point was allowed in each regression; 0.01 
was added to all of the years in the data series for the 
dependent variable where a zero value was observed. 
For data analysis, version 4.1.1 of the Joinpoint 
Regression program was used (14). 
 
Results 
We included 3,992 cases of the nine ICCC-3 
diagnostic groups, representing 38.7% of cancers 
diagnosed before the age of 20: 2,744 in children of 0 
to 14 years and 1,248 in adolescents of 15 to 19 years. 
Quality of cancer registration is elevated, with high 
proportions of microscopically verified diagnoses in 
all registries, ranging from 92.9% to 100%. Overall, 
94.5% of total cancers diagnosed in childhood and 
96.7% in adolescents were based on MV (Table 1a) 
and MV was even higher for non-CNS solid tumours 
(Table 1b). MV reached 100% for STS and GCTs, 
carcinoma and other epithelial tumours (COET) and 
melanoma, whereas was lower for retinoblastoma 
(85.5% in the first period and 74.5% in the second) in 
children (Table 1b). In adolescents, COET presented 
the lowest microscopically verified percentage. The 
proportion of cases in the group of other and 
unspecified cancers was 0.4% and 0.8% of total 
cancers in children and adolescents respectively 
(Table 2). 
 
Table 1a. Indices of data quality of all cancers by registry in children (age 0-14 years) and adolescents (aged 15-19 years). 
Cancer Registry Period Children Adolescents 
N %MV %DCO %NOS N %MV %DCO %NOS 
Albacete 1991-2007 156 92.9 0.6 1.3 91 93.4 1.1 0.0 
Asturias 1983-2007 530 93.8 1.3 0.0 308 97.4 1.3 0.0 
Comunitat Valenciana 1983-2007 2617 94.4 0.1 0.0 - - - - 
Basque Country 1986-2007 1128 93.3 0.6 0.4 606 96.5 0.0 0.5 
Girona 1983-2007 353 95.8 0.6 1.1 167 93.4 2.4 2.4 
Granada 1985-2007 467 95.9 0.2 0.0 276 97.1 0.7 0.0 
Mallorca 1988-2005 296 93.6 0.0 1.4 169 99.4 0.0 0.0 
Murcia 1983-2007 867 95.0 0.5 0.9 404 98.5 0.2 0.0 
Navarra 1983-2007 341 94.1 0.9 0.0 197 95.4 1.5 0.0 
Tarragona 1983-2007 383 96.6 0.5 0.0 210 95.7 1.0 0.0 
Zaragoza 1983-2003 544 95.4 0.9 0.0 208 96.6 0.5 2.4 
All cancer registries  1983-2007 7682 94.5 0.4 0.3 2636 96.7 0.7 0.5 
 
 
Table 1b. Indices of data quality of non-CNS solid tumours by diagnostic group and period in children (age 0-14 years) and adolescents 
(aged 15-19 years). 
Diagnostic group* Children Adolescents 
1983-1992 1993-2007 1983-1992 1993-2007 
N %MV %DCO %NOS N %MV %DCO %NOS N %MV %DCO %NOS N %MV %DCO %NOS 
Sympathetic Nervous System Tumours 220 97.7 0.5 0.0 382 97.6 0.0 0.0 9 100.0 0.0 0 13 100.0 0.0 0.0 
Retinoblastomas 76 85.5 0.0 2.6 110 74.5 0.0 1.8 - - - - - - - - 
Renal tumours 127 99.2 0.0 0.8 218 95.9 0.5 0.5 5 100.0 0.0 0 16 100.0 0.0 0.0 
Hepatic tumours 32 93.8 3.1 0.0 52 94.2 0.0 0.0 9 100.0 0.0 0 8 100.0 0.0 0.0 
Bone tumours 188 98.9 0.5 0.0 291 98.3 0.0 0.7 92 93.5 4.3 1.1 131 98.5 0.0 0.0 
Soft-tissue sarcoma 195 100.0 0.0 0.0 287 99.7 0.3 0.0 73 100.0 0.0 0 140 100.0 0.0 0.0 
Germ-cell tumours 90 100.0 0.0 0.0 124 98.4 0.0 0.0 71 97.2 0.0 1.4 183 99.5 0.0 0.0 
Carcinoma and other epithelial tumours 107 100.0 0.0 0.0 214 99.5 0.0 0.5 150 100.0 0.0 0 328 99.7 0.0 0.3 
Other and unspecified tumours 17 64.7 5.9 0.0 14 57.1 0.0 0.0 9 63.6 22.2 0 11 63.6 9.1 9.1 
Non-CND solid tumours 1052 97.4 0.4 0.3 1,692 96.2 0.1 0.4 419 97.3 1.4 0.5 842 99.0 0.1 0.2 
* According to the International Classification of Childhood Cancer, Third Edition. 
CNS: Central Nerous System; N: number of cases; MV: microscopic verification; DCO: death certificate only; (NOS): unspecified histology. 
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Table 2. Annual cancer incidence rate (per million) in children (age 0-14 years) and adolescents (age 15-19 years) by age and ICCC 
diagnostic group. Spanish cancer registries 1983-2007. Both sexes. 
  
  
Children   Adolescents  
    Age Specific Rates Crude 
Rate 
      
N % 0 1-4 5-9 10-14 ASRw ASRe M/F N % Rate M/F   
ALL CHILDHOOD CANCERS 7,682 100 242.6 203.6 121.4 124.2 149.3 157.0 155.0 1.2 * 2,623 100 187.8 1.3 * 
IV Sympathetic Nervous System tumours 602 7.8 82.0 22.0 3.5 1.2 11.7 14.6 13.9 1.1  22 0.8 1.6 1.0  
 IV(a) Neuroblastoma 593 98.5 81.3 21.9 3.3 1.1 11.5 14.5 13.7 1.1  12 54.5 0.9 1.0  
 IV(b) Other SNS 9 1.5 0.7 0.1 0.2 0.1 0.2 0.2 0.2 1.0  10 45.5 0.7 1.0  
V Retinoblastoma 186 2.4 18.8 9.1 0.9 0.1 3.6 4.6 4.3 1.2  0 0.0 0.0 0.0  
VI Renal tumours 345 4.5 21.1 15.5 4.1 1.0 6.7 8.1 7.7 1.0  21 0.8 1.5 1.3  
 VI(a) Wilms tumours 335 97.1 20.8 15.5 4.0 0.7 6.5 7.9 7.5 1.0  6 28.6 0.4 0.5  
 VI(b) Renal carcinoma 8 2.3 0.0 0.0 0.1 0.3 0.2 0.1 0.1 1.3  14 66.7 1.0 2.5  
 VI(c) Unspecified 2 0.6 0.3 0.0 0.0 0.0 0.0 0.1 0.1 -  1 4.7 0.1 -  
VII Hepatic tumours 84 1.1 7.9 2.8 0.7 0.7 1.6 1.9 1.8 1.6 * 17 0.6 1.2 2.4  
 VII(a) Hepatoblastoma 62 73.8 7.6 2.4 0.4 0.2 1.2 1.5 1.4 1.6  0 0.0 0.0 0.0  
 VII(b) Hepatic carcinoma 20 23.8 0.0 0.2 0.3 0.5 0.4 0.3 0.3 2.5  17 100.0 1.2 2.4  
 VII(c) Hepatic carcinoma 2 2.4 0.3 0.2 0.0 0.0 0.0 0.1 0.1 1.0  0 0.0 0.0 -  
VIII Malignant bone tumours 479 6.2 0.7 3.1 7.8 16.0 9.3 8.2 8.5 1.1  223 8.5 16.0 1.9 * 
 VIII(a) Osteosarcoma 205 42.8 0.0 0.6 2.7 7.9 4.0 3.4 3.6 1.0  107 48.0 7.7 2.1 * 
 VIII(c) Ewing sarcoma 243 50.7 0.7 1.8 4.7 7.2 4.7 4.2 4.4 1.2  86 38.6 6.2 2.2 * 
 VIII(b,d) Other specifed 21 4.4 0.0 0.3 0.3 0.6 0.4 0.4 0.4 1.7  20 9.0 1.4 1.0  
 VIII(e) Unspecifed 10 0.3 0.0 0.4 0.1 0.3 0.2 0.2 0.1 0.0  10 4.4 0.7 1.0  
IX Soft-tissue sarcoma 482 6.3 15.2 11.7 8.4 7.8 9.4 9.8 9.7 1.2  213 8.1 15.2 1.3  
 IX(a) Rhabdomyosarcoma 286 59.3 6.9 9.6 5.4 2.9 5.6 6.1 5.9 1.3 * 45 21.1 3.2 3.1 * 
 IX(b) Fibrosarcoma 51 10.6 5.3 0.3 0.7 1.0 1.0 1.0 1.0 1.5  19 8.9 1.4 0.7  
 IX(c) Kaposi sarcoma 1 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 -  3 1.4 0.2 -  
 IX(d) Other specifed 103 21.4 2.0 1.3 1.6 2.8 2.0 1.9 1.9 1.0  127 59.6 9.1 1.2  
 IX(e) Unspecifed 41 8.5 1.0 0.5 0.7 1.0 0.8 0.8 0.8 0.6  19 8.9 1.4 0.7  
X Germ-cell tumours 214 2.8 12.9 3.2 2.5 4.9 4.2 4.2 4.2 0.6 * 254 9.7 18.2 2.1 * 
 X(a) Intracranial tumours 44 20.6 2.3 0.3 1.0 0.8 0.9 0.8 0.8 1.8  16 6.3 1.1 4.3 * 
 X(b) Extracranial tumours 40 18.7 7.6 0.9 0.1 0.2 0.8 1.0 0.9 0.4 * 14 5.5 1.0 3.7 * 
 X(c) Gonadal germ-cell rumours 123 57.5 2.3 1.9 1.4 3.6 2.4 2.3 2.3 0.5 * 189 74.4 13.5 3.2 * 
 X(d) Gonadal carcinoma 5 2.3 0.0 0.0 0.0 0.3 0.1 0.1 0.1 0.0  27 10.6 1.9 0.0  
 X(e) Other and unspecifed 2 0.9 0.7 0.0 0.0 0.0 0.0 0.1 0.05 a  8 3.1 0.6 1.0  
XI Carcinomas and other epithelial tumours 321 4.2 2.0 1.5 3.6 12.3 6.2 5.3 5.6 0.7 * 478 18.2 34.2 0.5  
 XI(b) Thyroid carcinoma 121 37.7 0.0 0.3 1.2 5.1 2.4 1.9 2.1 0.6 * 171 35.8 12.2 0.3  
 XI(c) Nasopharingeal carcinoma 12 3.7 0.0 0.0 0.2 0.4 0.2 0.2 0.2 3.0  18 3.8 1.3 5.0 * 
 XI(d) Melanoma 84 26.2 1.0 0.9 1.1 2.7 1.6 1.5 1.5 0.7  116 24.3 8.3 0.5  
 XI(a,e,f) Other and unspecifed 104 32.4 1.0 0.3 1.0 4.2 2.0 1.7 1.8 0.7  173 36.2 12.4 0.8  
XII Other and unspecified tumours 31 0.4 2.3 0.8 0.2 0.5 0.6 0.7 0.6 1.6   20 0.8 1.4 2.3  
SOLID EXCEPT Central Nervous System 2,744 35.7 162.9 69.6 31.7 44.6 53.3 57.3 56.3 1.0   1,248 47.6 89.3 1.1   
* Sex ratio (M/F) significative (p<0.05). 
ICCC: International Clasificacion of Chidhood Cancer third edition; ASR: age standardized rate (ARSw: with world pop. ASRe with european pop.) 
 
 
Overall ASRe for solid tumours –except those of 
CNS- in childhood from 1983 to 2007 was 56.3 cases 
per million child-year, with the highest incidence 
among infants (162.9) and the lowest in the 5-9 years 
age group (31.7) (Table 2). The age specific rate for 
adolescents was 89.3 per million. No significant 
differences in the overall male to female (M/F) ASRe 
ratio in children and adolescents were observed for 
these tumours. In children, hepatic tumours and 
rhabdomyosarcoma presented higher incidence in 
males while incidence of GCT and thyroid carcinoma 
was higher in females. On the other hand, adolescent 
males presented higher incidence of BT, RMS, GCT 
and nasopharyngeal carcinoma. 
The commonest types of cancer among those 
included in this study in childhood were NB 
accounting for 7.7% of total childhood cancers (ASRe: 
13.7) followed by STS (6.3%), BT (6.2%) and WT (4.4%) 
(Table 2). Rhabdomyosarcoma was the commonest 
STS, and Ewing sarcoma and osteosarcoma accounted 
for 93.5% of all BTs. By age groups, NB was the most 
frequently diagnosed tumour in infants and also 
before the 5th birthday, followed by Wilms tumour, 
STS and Retinoblastoma. STS and BT were the 
commonest at 5-9 years of age, and BT and COET at 
10-14 (Figure 1). The different distributions in age 
specific rates of all nine ICCC-3 diagnostic groups can 
be seen in figure 1 and information on incidence can 
be found in table 2. The distribution of cancers that 
occurred among 15-19 year-olds was quite different 
from that of children (Figure 2). COET presented the 
highest incidence, followed by GCT, BT and STS. 
These four diagnostic groups accounted for 94% of 
total non-CNS solid tumours in adolescents. Among 
them, osteosarcoma and Ewing sarcoma were the 
most frequent BT, gonadal GCT were also the most 
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frequent in the GCT group and other specified 
sarcomas were the commonest STS. Liver cancers are 
extremely rare in children and adolescents and 
presented the lowest incidence of these solid cancers. 
Hepatoblastomas resulted the most frequent in 
children under five and hepatic carcinoma over the 
age of 10. Incidence rates of embryonal cancers 
prevailing among young children decreased with age 
whereas solid tumours more frequent in adolescents 
presented very low incidence rates among the 
youngest children. 
 
 
Figure 1. Age-specific incidence rates (per million) of non-CNS solid tumours by type of tumour, in children and adolescents. Period 1983-2007. Both 
sexes. 
 
Figure 2. Relative frequencies (%) of the 9 ICCC groups of Solid tumours, except CNS, in children and adolescents. Period 1983-2007. Both Sexes 
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Overall childhood non-CNS solid tumours 
incidence time trends showed significant increases 
over the period study with an APC of 2.6 (CI: 1.7; 3.6) 
up to 1996 (CI: 1993-2001) and no significant increases 
afterwards. There was also an APC of 2.7% (CI: 1.4; 
4.0) up to 1998 (CI: 1990-2001) in children under 5 
years of age. Significant increase was observed all 
along the period in children aged 10-14 years and 
adolescents with APCs of 1.6% (CI: 0.7; 2.6) and 2.7% 
(CI: 1.8; 3.6) respectively (data not shown). The 
evolution of incidence by three years period and 
tumour can be seen in figure 3. It can be observed an 
increasing trend up to the period 1998-2002 for NB 
and GCT in children and for GCT and STS in 
adolescents up to the last period (2003-2007). Among 
the studied tumours, NB and the group of COET 
presented a significant trend in children, with APCs 
of 1.4% and 3.8% respectively. Other ICCC-3 groups 
such as renal or STS, BT or GCT showed no significant 
changes over time. In adolescents there were 
significant increases in STS, GCT and COEFT with 
APCs of 3.2%, 4.4% and 3.5% respectively and in all 
subcategories of these groups (Table 3).  
Table 3. Number of cases (N) and annual percentage change 
(APC) in incidence rates of non-CNS solid tumours in children 
(age 0-14 years) and adolescents (age 15-19 years) by ICCC 
diagnostic groups. Period 1983-2007. Both sexes. 
Diagnostic groups Children Adolescents 
N APC N APC 
Neuroblastoma (IVa) 593 1.4 (0.1; 2.7) - - 
Retinoblastoma (V) 186 -0.2 (-2.2; 1.9) - - 
Renal Tumours (VI) 345 1.4 (-0.1; 2.9) 21 0.3 (-2.5; 3.2) 
       Wilms tumours (VIa) 335 1.3 (-0.2; 2.8) 6 - 
Hepatic Tumours (VII) 84 0.3 (-3.0; 5.6) 17 2.4 (-0.3; 5.3) 
       Hepatoblastoma (VIIa) 62 -0.2 (-3.4; 3.2) - - 
Bone Tumours (VIII) 479 1.0 (-0.6; 2.7) 223 -0.9 (-2.9; 1.1) 
       Osteosarcoma (VIIIa) 205 1.1 (-1.0; 3.2) 107 -0.4 (-2.5; 1.8) 
       Ewing tumours (VIIIc) 243 1.7 (-1.1; 3.2) 86 -1.0 (-2.7; 0.7) 
Soft-tissue sarcoma (IX) 482 1.1 (-0.2; 2.3) 213 3.2 (1.1; 5.3) 
       Rhabdomyosarcoma (IXa) 286 0.1 (-1.8; 1.9) 45 3.2 (0.2; 6.2) 
       Soft tissue Sarcoma no RMS (IXb-e) 155 2.8 (0.5; 5.1) 168 3.3 (1.0; 5.6) 
Germ-cell tumours (X) 214 0.6 (-1.2; 2.5) 254 4.4 (2.1; 6.9) 
Epitelial neoplasms and melanoma 
(XI) 
321 3.8 (2.0; 5.7) 478 3.5 (2.1; 4.9) 
       Thyroid carcinoma (XIb) 121 3.0 (-0.4; 6.6) 171 1.8 (-0.4; 4.0) 
       Malignant melanoma (XId) 84 5.2 (2.4; 8.1) 116 5.9 (2.6; 9.3) 
CNS: Central Nervous System; ICCC: International Clasificacion of Chidhood 
Cancer third edition. 
 
 
Figure 3. Age-standardized incidence rates (per million) of non-Central Nervous System solid tumours in children (age 0-14 years)(3a) and adolescents 
(age 15-19 years)(3b) by type of tumour. Period 1983-2007. Both sexes. 
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Discussion 
Grouping all childhood cancer together may be 
helpful to understand the overall cancer burden in a 
population, but it masks the contributions of each 
tumour type. Therefore, this paper focuses on specific 
histological groups that are not the most frequent in 
childhood but represent one third of the incidence 
altogether and almost half of all cancer diagnosed in 
adolescents. The incidence rates estimated are derived 
from most of the data available from the 
population-based cancer registries of Spain, which 
covers almost one third of the Spanish population. 
Even so, the small number of cases for some of the 
tumours studied hinders the interpretation of data. 
Therefore and although we cannot ignore the fact that 
some changes in the incidence have actually occurred, 
these did not achieve statistical significance due to the 
study size.  
Neuroblastoma is the most common childhood 
cancer diagnosed during the first year of life. Its 
incidence has increased in childhood, particularly in 
the youngest (0-4 years old). Some increases have 
been described, particularly in the first year of life 
(15), in Europe. Incidence rates are similar to the ones 
reported internationally in Southern Europe (16, 17), 
higher than those in USA (6) and UK (18) and lower 
than the ones for Australia (19). The improvement in 
diagnostic techniques may have contributed to the 
perceived increase of incidence, but the detection of 
latent or asymptomatic tumours, especially in very 
young children, has uncovered tumours that might 
have not otherwise been diagnosed (20). 
Retinoblastoma incidence has been stable in the 
study period with a rate similar to that of France, UK 
and Italy (16, 17, 18) and higher to that of USA and 
Australia (6, 19). Intraocular retinoblastoma is a 
highly curable malignancy and current treatments are 
aimed to preserve vision (21, 22). This could explain 
the lower percentage of MV in the most recent period. 
Renal tumours incidence, and Wilms tumour 
(WT), the most frequent in this group, presented non 
statistical significance increase in the age group 0-5 
years. Incidence described in Italy, USA and Australia 
(17, 19, 23) was similar to the Spanish one.  
The two main malignant hepatic tumours in 
children are hepatoblastoma and hepatocellular 
carcinoma. Incidence rates observed in this study 
were close to the figures reported by Lacour et al (16) 
for France and Germany (24) in 2000-2004 and slightly 
higher than those of USA and Switzerland.  
The total incidence of malignant bone tumours 
in childhood, the increasing incidence with age and 
the sex ratio close to one were similar to that reported 
in other countries (17, 25). But contrary to most 
countries figures, in our study, the most common 
malignant bone tumours in children was Ewing 
sarcoma (not osteosarcoma) before the age of 10. This 
different distribution could be due to changes in 
registration practice or diagnostic improvement, but it 
is in fact also present in more recent data available 
from the Spanish Registry of Childhood Tumours 
which comes directly from the pediatric oncologists, 
so presently we cannot give a clear explanation for 
this phenomenon. A significant increase in incidence 
was observed for bone tumours only at age 10-14 
years over the study period, with no significant 
increases in all other age groups. These incidence 
changes may reflect random variation, better 
diagnostic procedures or changes in unknown risk 
factors, and therefore highlight the need for more 
research into the etiology of childhood cancer (19). 
Soft-tissue sarcomas are a heterogeneous group 
of neoplasms developing from mesenchymal cells at 
any site in the body. Neoplasms are categorized in 
two broad groups: RMS and non-RMS. ASRw for 
childhood in Spain was similar to those observed in 
Italy 2003-2008 (17), France (26) and Australia (19). 
Overall STS incidence increased over time, 
statistically significant only in the oldest age group, 
especially in adolescents. This increase was consistent 
with those observed in the SEER Program of the USA 
(23) and Europe (26) in previous periods. Advances in 
laboratory techniques have allowed better 
characterization of the soft-tissue sarcomas, which 
could contribute to explain temporal trends of 
incidence (as well as, perhaps, misclassification). 
Germ-cell tumours, showed age specific rates 
lower to those reported by France (16). The incidence 
was higher in infants, with a rate of 12.2, and it 
decreased with age, thus being the lowest rate in the 
5-9 year-old group. GCT was more frequent in girls 
during childhood and in boys during adolescence, as 
in other countries (6, 16). 
Different entities were included in the group of 
carcinomas and other epithelial tumours. Thyroid 
carcinoma is the most frequent tumour, similar to 
Italy (17). As it happens in other countries such as in 
Italy or France (16), in Spain thyroid carcinomas were 
more frequent in girls. Malignant melanoma is also 
more frequent in girls, similarly to most European 
countries (27), although as it happens in our study, 
gender difference did not reach statistical significance. 
The 10-14 year–old group showed the highest 
incidence in children, which continued rising up until 
adolescence, but yet this was lower than that reported 
in Europe (27) and also in more recent data from Italy, 
and was similar to France. The significant increase of 
this cancer was higher than that observed in Italy, and 
showed significant increases not only in adolescents 
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but also in children, unlike for other European 
countries. More recent data from USA (28) have 
shown a significant decrease in melanoma in 
population less than 20 years of age, except in the 
south where an increase in children and adolescent 
has been observed. Exposure to ultraviolet radiation 
has increased over the past decades and could explain 
part of the incidence of adolescent melanoma, but 
does not reveal much about the risk factors for child 
melanoma, which has also increased in Spain. The 
increasing trend of melanoma incidence observed in 
this study may be part of a mixture of increasing 
exposure to risk factors combined with improved 
surveillance.  
Conclusion 
Overall childhood cancer included in this study 
showed an increasing trend in incidence along the 
period 1983-1996, with no posterior significant rise, 
while the incidence in adolescents increased 
significantly over the whole period. The increasing 
trend observed up to 1998 for NB in children under 5 
years of aged, due possible to improving diagnostic 
methods, could explain, part of the phenomenon. On 
the other hand, increasing risk of STS in older children 
and adolescents, as well as skin melanoma might 
explain the increasing trend all along the period, in 
population older than 10 years. Several specific 
tumours showed significant rises or decrements, and 
it should be highlighted that although there has been 
an increase in the incidence of some other tumours, 
this did not achieve statistical significance due to the 
small number of cases involved. The results of the 
analysis performed in this paper give a descriptive 
shot of some rare cancers from the Spanish children 
and adolescents. It points out the relevance of using 
population-based cancer registries to identify 
differences in incidence that could be related to risk 
factors or the management of the process of the 
disease. Cancer registries are extremely valuable 
surveillance tools and provide useful and reliable 
information for research and planning (29). 
Centralization of diagnostic procedures such as 
histopathology and molecular biology, for some rare 
neoplasm of this heterogeneous group could also 
contribute to improve the quality of diagnosis. Our 
study highlights the need for continuous surveillance 
of these cancers, to enable correct interpretation of 
time trends. 
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